Volume 6 Supplement 1

Symposium Mammographicum 2004

Open Access

Mammographic tumour features can reliably predict the long-term outcome of women with 1–14 mm invasive breast cancer: suggestions for revision of current therapeutic practice and the TNM classification system

  • L Tabar1,
  • THH Chen2,
  • MF Yen3,
  • T Tot4,
  • TH Tung2,
  • LS Chen2,
  • YH Chiu2,
  • SW Duffy3 and
  • RA Smith5
Breast Cancer Research20046(Suppl 1):P63

https://doi.org/10.1186/bcr882

Published: 14 July 2004

We studied the 24-year survival of 714 women with 1–14 mm invasive breast cancer according to mammographic features, including appearance of calcifications and masses. The most common mammographic feature was a stellate lesion with no associated calcifications (420 cases, 59%). Patients with stellate lesions had excellent long-term survival (95%). Casting-type calcifications were observed in 52 (7%) cases and were significantly associated with a positive lymph node status, poorer histological grade, and increased risk of breast cancer death (hazard ratio = 9.19, 95% confidence interval = 4.18–20.17). Except for tumours with casting type calcifications, all tumours less than 10 mm had excellent survival, regardless of node status, histological grade or treatment. For those with casting-type calcifications, survival was poorer even with 1–9 mm tumours (72% at 20 years). For 10–14 mm tumours, 20-year survival was 52% for those with casting calcifications, and 86–100% otherwise. Small invasive cancers accompanied by casting-type calcifications have unexpectedly poor prognosis for their size. Neoductgenesis offers a possible explanation for the unexpectedly poor outcome. There is a need to develop treatment protocols for this group. After exclusion of tumours with casting-type calcifications, the remainder have extremely good prognosis when treated with surgery and no adjuvant therapy.

Authors’ Affiliations

(1)
Mammography Department, Central Hospital
(2)
Graduate Institute of Preventive Medicine, National Taiwan University
(3)
Cancer Research UK Centre For Epidemiology, Mathematics and Statistics
(4)
Pathology Department, Falun Central Hospital
(5)
American Cancer Society

Copyright

© BioMed Central 2004

Advertisement